FGFR3 and Alzheimer disease: Based on the scopolamine-induced cognitive impairment, we studied the behavioral phenotype of AD model mice and discovered that GPCRAC extracts at high doses markedly alleviate AD-related cholinergic dysfunction, as demonstrated by increased Ach content and ChAT activity and decreased AchE activity.